Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Sells $438,898.44 in Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) CEO Christopher Peetz sold 9,102 shares of the company’s stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $48.22, for a total value of $438,898.44. Following the completion of the sale, the chief executive officer now owns 115,920 shares of the company’s stock, valued at $5,589,662.40. This trade represents a 7.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Christopher Peetz also recently made the following trade(s):

• On Friday, January 24th, Christopher Peetz sold 6,837 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $47.92, for a total value of $327,629.04.
• On Tuesday, January 7th, Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $42.82, for a total value of $320,678.98.

Mirum Pharmaceuticals Stock Up 3.3 %

Shares of NASDAQ MIRM traded up $1.62 during mid-day trading on Tuesday, hitting $50.21. The company had a trading volume of 410,214 shares, compared to its average volume of 511,828. The company has a market capitalization of $2.41 billion, a PE ratio of -24.86 and a beta of 0.96. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15. Mirum Pharmaceuticals, Inc. has a 1-year low of $23.14 and a 1-year high of $50.34. The business’s 50-day simple moving average is $44.39 and its 200 day simple moving average is $42.02.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to analysts’ expectations of $81.99 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. The company’s revenue for the quarter was up 89.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.57) earnings per share. On average, analysts predict that Mirum Pharmaceuticals, Inc. will post -1.44 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a report on Wednesday, November 13th. Leerink Partners upped their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Robert W. Baird upped their price objective on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, Citigroup upped their price objective on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $57.10.

Institutional Trading of Mirum Pharmaceuticals

Several hedge funds have recently modified their holdings of MIRM. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Mirum Pharmaceuticals by 22.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,725 shares of the company’s stock valued at $67,000 after acquiring an additional 318 shares in the last quarter. R Squared Ltd purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at $69,000. Avanza Fonder AB purchased a new position in Mirum Pharmaceuticals in the fourth quarter valued at $189,000. Y Intercept Hong Kong Ltd purchased a new position in Mirum Pharmaceuticals in the third quarter valued at $215,000. Finally, Creative Planning purchased a new position in Mirum Pharmaceuticals in the third quarter valued at $249,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.